[8-K] Live Oak Bancshares, Inc. Reports Material Event
Aclaris Therapeutics (Nasdaq: ACRS) has filed a Form 8-K to inform investors that it will host a conference call on 29 Jul 2025 to review top-line data from its Phase 2a study of ATI-2138, an oral covalent ITK/JAK3 inhibitor for moderate-to-severe atopic dermatitis. Two items are furnished: Exhibit 99.1 (investor presentation) and Exhibit 99.2 (press release). Under Reg FD, Items 7.01 and 8.01 are furnished鈥攏ot filed鈥攕o the information is not subject to Exchange Act liability nor automatically incorporated into other SEC reports.
The 8-K contains no numerical efficacy, safety, or financial metrics. Investors must consult the accompanying exhibits or join the conference call for detailed results. No changes to financial statements or previously issued guidance are included.
Aclaris Therapeutics (Nasdaq: ACRS) ha presentato un modulo 8-K per informare gli investitori che terr脿 una conference call il 29 luglio 2025 per esaminare i dati preliminari del suo studio di Fase 2a su ATI-2138, un inibitore orale covalente ITK/JAK3 per la dermatite atopica da moderata a grave. Sono forniti due documenti: l'Esibizione 99.1 (presentazione per investitori) e l'Esibizione 99.2 (comunicato stampa). Ai sensi del Regolamento FD, gli articoli 7.01 e 8.01 sono forniti, non depositati, pertanto le informazioni non sono soggette a responsabilit脿 ai sensi dello Exchange Act n茅 automaticamente incorporate in altri rapporti SEC.
Il modulo 8-K non contiene dati numerici su efficacia, sicurezza o metriche finanziarie. Gli investitori devono consultare le esibizioni allegate o partecipare alla conference call per ottenere risultati dettagliati. Non sono incluse modifiche ai bilanci o alle precedenti indicazioni finanziarie.
Aclaris Therapeutics (Nasdaq: ACRS) ha presentado un Formulario 8-K para informar a los inversores que realizar谩 una llamada de conferencia el 29 de julio de 2025 para revisar los datos preliminares de su estudio de Fase 2a sobre ATI-2138, un inhibidor covalente oral ITK/JAK3 para dermatitis at贸pica de moderada a grave. Se proporcionan dos documentos: el Anexo 99.1 (presentaci贸n para inversores) y el Anexo 99.2 (comunicado de prensa). Seg煤n el Reglamento FD, los 铆tems 7.01 y 8.01 se proporcionan, no se presentan, por lo que la informaci贸n no est谩 sujeta a responsabilidad bajo la Ley de Intercambio ni se incorpora autom谩ticamente en otros informes de la SEC.
El 8-K no contiene m茅tricas num茅ricas de eficacia, seguridad o financieras. Los inversores deben consultar los anexos adjuntos o unirse a la llamada de conferencia para obtener resultados detallados. No se incluyen cambios en los estados financieros ni en las gu铆as previamente emitidas.
Aclaris Therapeutics (雮橃姢雼�: ACRS)電� 2025雲� 7鞗� 29鞚检棎 欷戨摫霃勳棎靹� 欷戩 鞎勴啝頂� 頂茧秬鞐� 旃橂毳� 鞙勴暅 瓴疥惮鞖� 瓿奠湢 瓴绊暕 ITK/JAK3 鞏奠牅鞝� ATI-2138鞚� 2a靸� 鞁滍棙 欤检殧 瓴瓣臣毳� 瓴�韱犿晿旮� 鞙勴暅 旎嵓霟办姢 旖滌潉 臧滌禍頃� 鞓堨爼鞛勳潉 韴瀽鞛愳棎瓴� 鞎岆Μ旮� 鞙勴暣 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 霊� 臧�歆� 鞛愲臧� 鞝滉车霅╇媹雼�: 鞝勳嫓氍� 99.1(韴瀽鞛� 頂勲爤鞝犿厡鞚挫厴)瓿� 鞝勳嫓氍� 99.2(氤措弰鞛愲). Reg FD鞐� 霐半澕 頃 7.01 氚� 8.01鞚� 鞝滌稖霅� 瓴冹澊 鞎勲媹霛� 鞝滉车霅� 瓴冹溂搿�, 霐半澕靹� 鞚� 鞝曤炒電� 歃濌秾瓯半灅氩曥儊 毂呾瀯 雽�靸侅澊 鞎勲媹氅� 雼るジ SEC 氤搓碃靹滌棎 鞛愲彊鞙茧 韽暔霅橃 鞎婌姷雼堧嫟.
8-K 氍胳劀鞐愲姅 靾橃箻搿� 霅� 須姤, 鞎堨爠靹� 霕愲姅 鞛 歆�響滉皜 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟. 韴瀽鞛愲摛鞚� 靸侅劯頃� 瓴瓣臣毳� 鞙勴暣 觳秬霅� 鞝勳嫓氍检潉 彀胳“頃橁卑雮� 旎嵓霟办姢 旖滌棎 彀胳棳頃挫暭 頃╇媹雼�. 鞛鞝滍憸雮� 鞚挫爠鞐� 氚滍憸霅� 臧�鞚措崢鞀れ潣 氤�瓴� 靷暛鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Aclaris Therapeutics (Nasdaq : ACRS) a d茅pos茅 un formulaire 8-K pour informer les investisseurs qu'une conf茅rence t茅l茅phonique aura lieu le 29 juillet 2025 afin de passer en revue les donn茅es pr茅liminaires de son 茅tude de phase 2a sur ATI-2138, un inhibiteur oral covalent ITK/JAK3 pour la dermatite atopique mod茅r茅e 脿 s茅v猫re. Deux documents sont fournis : l鈥橢xhibit 99.1 (pr茅sentation aux investisseurs) et l鈥橢xhibit 99.2 (communiqu茅 de presse). Conform茅ment au r猫glement FD, les items 7.01 et 8.01 sont fournis, non d茅pos茅s, ce qui signifie que l鈥檌nformation n鈥檈st pas soumise 脿 la responsabilit茅 au titre de l鈥橢xchange Act ni automatiquement int茅gr茅e dans d鈥檃utres rapports aupr猫s de la SEC.
Le formulaire 8-K ne contient aucune donn茅e chiffr茅e sur l鈥檈fficacit茅, la s茅curit茅 ou les indicateurs financiers. Les investisseurs doivent consulter les documents joints ou participer 脿 la conf茅rence t茅l茅phonique pour obtenir des r茅sultats d茅taill茅s. Aucune modification des 茅tats financiers ou des pr茅visions pr茅c茅demment publi茅es n鈥檈st incluse.
Aclaris Therapeutics (Nasdaq: ACRS) hat ein Formular 8-K eingereicht, um Investoren dar眉ber zu informieren, dass am 29. Juli 2025 eine Telefonkonferenz stattfinden wird, um die vorl盲ufigen Daten der Phase-2a-Studie von ATI-2138, einem oralen kovalenten ITK/JAK3-Inhibitor f眉r mittelschwere bis schwere atopische Dermatitis, zu besprechen. Zwei Anlagen werden bereitgestellt: Anlage 99.1 (Investorpr盲sentation) und Anlage 99.2 (Pressemitteilung). Gem盲脽 Reg FD werden die Punkte 7.01 und 8.01 bereitgestellt, nicht eingereicht, sodass die Informationen nicht der Haftung nach dem Exchange Act unterliegen und nicht automatisch in andere SEC-Berichte aufgenommen werden.
Das 8-K enth盲lt keine numerischen Daten zu Wirksamkeit, Sicherheit oder Finanzen. Investoren m眉ssen die beigef眉gten Anlagen einsehen oder an der Telefonkonferenz teilnehmen, um detaillierte Ergebnisse zu erhalten. 脛nderungen an Finanzberichten oder zuvor ver枚ffentlichten Prognosen sind nicht enthalten.
- Announcement of top-line Phase 2a results for ATI-2138 signals ongoing development progress and upcoming clinical visibility.
- Filing lacks any efficacy or safety data, leaving investors unable to gauge clinical success or valuation impact.
Insights
TL;DR: Filing announces forthcoming Phase 2a data; impact indeterminate until actual numbers released.
Pipeline progress matters in biotech valuations, and ATI-2138鈥檚 emergence from Phase 2a is a gating event. However, the 8-K omits efficacy or safety readouts, preventing assessment of clinical or commercial viability. Investors should withhold judgment until Exhibit 99.2 is reviewed or management comments on response rates, pruritus scores and adverse events.
TL;DR: Procedural 8-K; no immediate valuation catalyst without data.
The filing satisfies Reg FD by alerting the market to an upcoming disclosure. Because the information is furnished, it does not trigger SEC liability or automatic inclusion in future filings. Absent quantitative results, share-price impact is likely muted until the press release or call provides clarity on trial success, timeline to Phase 3 and funding needs.
Aclaris Therapeutics (Nasdaq: ACRS) ha presentato un modulo 8-K per informare gli investitori che terr脿 una conference call il 29 luglio 2025 per esaminare i dati preliminari del suo studio di Fase 2a su ATI-2138, un inibitore orale covalente ITK/JAK3 per la dermatite atopica da moderata a grave. Sono forniti due documenti: l'Esibizione 99.1 (presentazione per investitori) e l'Esibizione 99.2 (comunicato stampa). Ai sensi del Regolamento FD, gli articoli 7.01 e 8.01 sono forniti, non depositati, pertanto le informazioni non sono soggette a responsabilit脿 ai sensi dello Exchange Act n茅 automaticamente incorporate in altri rapporti SEC.
Il modulo 8-K non contiene dati numerici su efficacia, sicurezza o metriche finanziarie. Gli investitori devono consultare le esibizioni allegate o partecipare alla conference call per ottenere risultati dettagliati. Non sono incluse modifiche ai bilanci o alle precedenti indicazioni finanziarie.
Aclaris Therapeutics (Nasdaq: ACRS) ha presentado un Formulario 8-K para informar a los inversores que realizar谩 una llamada de conferencia el 29 de julio de 2025 para revisar los datos preliminares de su estudio de Fase 2a sobre ATI-2138, un inhibidor covalente oral ITK/JAK3 para dermatitis at贸pica de moderada a grave. Se proporcionan dos documentos: el Anexo 99.1 (presentaci贸n para inversores) y el Anexo 99.2 (comunicado de prensa). Seg煤n el Reglamento FD, los 铆tems 7.01 y 8.01 se proporcionan, no se presentan, por lo que la informaci贸n no est谩 sujeta a responsabilidad bajo la Ley de Intercambio ni se incorpora autom谩ticamente en otros informes de la SEC.
El 8-K no contiene m茅tricas num茅ricas de eficacia, seguridad o financieras. Los inversores deben consultar los anexos adjuntos o unirse a la llamada de conferencia para obtener resultados detallados. No se incluyen cambios en los estados financieros ni en las gu铆as previamente emitidas.
Aclaris Therapeutics (雮橃姢雼�: ACRS)電� 2025雲� 7鞗� 29鞚检棎 欷戨摫霃勳棎靹� 欷戩 鞎勴啝頂� 頂茧秬鞐� 旃橂毳� 鞙勴暅 瓴疥惮鞖� 瓿奠湢 瓴绊暕 ITK/JAK3 鞏奠牅鞝� ATI-2138鞚� 2a靸� 鞁滍棙 欤检殧 瓴瓣臣毳� 瓴�韱犿晿旮� 鞙勴暅 旎嵓霟办姢 旖滌潉 臧滌禍頃� 鞓堨爼鞛勳潉 韴瀽鞛愳棎瓴� 鞎岆Μ旮� 鞙勴暣 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 霊� 臧�歆� 鞛愲臧� 鞝滉车霅╇媹雼�: 鞝勳嫓氍� 99.1(韴瀽鞛� 頂勲爤鞝犿厡鞚挫厴)瓿� 鞝勳嫓氍� 99.2(氤措弰鞛愲). Reg FD鞐� 霐半澕 頃 7.01 氚� 8.01鞚� 鞝滌稖霅� 瓴冹澊 鞎勲媹霛� 鞝滉车霅� 瓴冹溂搿�, 霐半澕靹� 鞚� 鞝曤炒電� 歃濌秾瓯半灅氩曥儊 毂呾瀯 雽�靸侅澊 鞎勲媹氅� 雼るジ SEC 氤搓碃靹滌棎 鞛愲彊鞙茧 韽暔霅橃 鞎婌姷雼堧嫟.
8-K 氍胳劀鞐愲姅 靾橃箻搿� 霅� 須姤, 鞎堨爠靹� 霕愲姅 鞛 歆�響滉皜 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟. 韴瀽鞛愲摛鞚� 靸侅劯頃� 瓴瓣臣毳� 鞙勴暣 觳秬霅� 鞝勳嫓氍检潉 彀胳“頃橁卑雮� 旎嵓霟办姢 旖滌棎 彀胳棳頃挫暭 頃╇媹雼�. 鞛鞝滍憸雮� 鞚挫爠鞐� 氚滍憸霅� 臧�鞚措崢鞀れ潣 氤�瓴� 靷暛鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Aclaris Therapeutics (Nasdaq : ACRS) a d茅pos茅 un formulaire 8-K pour informer les investisseurs qu'une conf茅rence t茅l茅phonique aura lieu le 29 juillet 2025 afin de passer en revue les donn茅es pr茅liminaires de son 茅tude de phase 2a sur ATI-2138, un inhibiteur oral covalent ITK/JAK3 pour la dermatite atopique mod茅r茅e 脿 s茅v猫re. Deux documents sont fournis : l鈥橢xhibit 99.1 (pr茅sentation aux investisseurs) et l鈥橢xhibit 99.2 (communiqu茅 de presse). Conform茅ment au r猫glement FD, les items 7.01 et 8.01 sont fournis, non d茅pos茅s, ce qui signifie que l鈥檌nformation n鈥檈st pas soumise 脿 la responsabilit茅 au titre de l鈥橢xchange Act ni automatiquement int茅gr茅e dans d鈥檃utres rapports aupr猫s de la SEC.
Le formulaire 8-K ne contient aucune donn茅e chiffr茅e sur l鈥檈fficacit茅, la s茅curit茅 ou les indicateurs financiers. Les investisseurs doivent consulter les documents joints ou participer 脿 la conf茅rence t茅l茅phonique pour obtenir des r茅sultats d茅taill茅s. Aucune modification des 茅tats financiers ou des pr茅visions pr茅c茅demment publi茅es n鈥檈st incluse.
Aclaris Therapeutics (Nasdaq: ACRS) hat ein Formular 8-K eingereicht, um Investoren dar眉ber zu informieren, dass am 29. Juli 2025 eine Telefonkonferenz stattfinden wird, um die vorl盲ufigen Daten der Phase-2a-Studie von ATI-2138, einem oralen kovalenten ITK/JAK3-Inhibitor f眉r mittelschwere bis schwere atopische Dermatitis, zu besprechen. Zwei Anlagen werden bereitgestellt: Anlage 99.1 (Investorpr盲sentation) und Anlage 99.2 (Pressemitteilung). Gem盲脽 Reg FD werden die Punkte 7.01 und 8.01 bereitgestellt, nicht eingereicht, sodass die Informationen nicht der Haftung nach dem Exchange Act unterliegen und nicht automatisch in andere SEC-Berichte aufgenommen werden.
Das 8-K enth盲lt keine numerischen Daten zu Wirksamkeit, Sicherheit oder Finanzen. Investoren m眉ssen die beigef眉gten Anlagen einsehen oder an der Telefonkonferenz teilnehmen, um detaillierte Ergebnisse zu erhalten. 脛nderungen an Finanzberichten oder zuvor ver枚ffentlichten Prognosen sind nicht enthalten.
(Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
| Not Applicable | ||
| (Former name or former address, if changed since last report) | ||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Exhibit Number | Description | |||||||
1.1 | Underwriting Agreement, dated July 28, 2025 | |||||||
99.1 | Press Release dated July 28, 2025 issued by Live Oak Bancshares, Inc. | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
| LIVE OAK BANCSHARES, INC. | ||||||||
| Date: July 29, 2025 | By: | /s/ Walter J. Phifer | ||||||
| Walter J. Phifer Chief Financial Officer | ||||||||
Source:
FAQ
What did Aclaris Therapeutics (ACRS) announce in its 8-K?
Is the actual ATI-2138 Phase 2a data included in the filing?
What is ATI-2138?
Are the furnished materials considered "filed" with the SEC?
Will this 8-K affect Aclaris鈥檚 financial statements?
